Published in Sci Rep on November 13, 2015
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
CIP2A inhibits PP2A in human malignancies. Cell (2007) 5.28
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74
Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol (1992) 2.99
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 2.08
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res (2007) 2.04
Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem (2003) 1.90
Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol (2004) 1.62
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem (1994) 1.57
Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res (2010) 1.47
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res (2010) 1.39
SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev (2008) 1.34
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene (2011) 1.26
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci U S A (2014) 1.25
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov (2012) 1.22
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol (2014) 1.21
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood (2011) 1.18
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res (2014) 1.12
Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther (2011) 1.10
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. Br J Cancer (2014) 1.06
Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res (2014) 1.01
Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br J Cancer (2013) 0.95
A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma. J Vet Med Sci (2012) 0.95
Differentiation and stromal-induced growth promotion of murine prostatic tumors. Prostate (2002) 0.88
Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells. J Biol Chem (2014) 0.87
Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau. J Biol Chem (2014) 0.84
The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer. Mol Cancer Ther (2014) 0.83
Retracted CIP2A mediates prostate cancer progression via the c-MYC signaling pathway. Tumour Biol (2015) 0.80